On November 14, 2018, a group of seven people, including Director Ma Qiujuan, from the medical bioinventory review department of Patent examination Examination of the state Cooperation (Beijing) Center of the Patent Office, CNIPA, came to Hangzhou Future Sci-Tech City to conduct in-depth research on how to strengthen intellectual property protection and interpret relevant national patent laws and regulations in the process of independent innovation of science and technology enterprises.
Dr. Hu Fang, Chairman of ConVerd, introduced that, ConVerd’s team has always been attaching great importance to the protection of intellectual property and carrying out technical cooperation and independent innovation in accordance with international market rules since the completion of the whole process development of the world's first oncolytic virus new drug. Since founded in 2012, Hangzhou ConVerd has successively completed four collaborative developments of innovative drugs from preclinical to phase II clinical trials. , Since transforming to independent innovation in 2015, in more than two years, the company has constructed three complete oncolytic virus project platforms (vaccinia virus, adenovirus, and herpes virus), and two cells immunotherapy platforms (TCR-T, and NK, CAR-NK, CAR-T) and declared nearly 30 patents in 18 patent families.
Director Ma Qiujuan points out that the state will promote enterprise technology innovation as a long-term strategic national policy. The IP Office will also vigorously promote technological innovation and intellectual property protection in accordance with national industrial policies, fully understand the actual situation and needs of technological innovation of enterprises, and protect the independent innovation and international competition of Chinese technology enterprises. Director Ma and her research team also interpreted the relevant national intellectual property protection policies, and fully affirmed the company's intellectual property protection work and provided valuable guidance.